Eric brings with him 20 years of experience training and meeting management and has worked in clinical research for almost 25 years. The global reach of this experience (Eric has trained in six continents) makes him the partner of choice to work with. Eric combines soft skills with personal responsibility in every training.
Gabriele is currently the Managing Director of CRQS (Creative Regulatory & Quality Solutions), specializing in Strategic Regulatory Affairs, Quality Management, Organizational Development and Change Management. She has 38 years of experience under her belt in pharmaceutical development, with 29 years in pharmaceutical industry (Merck KGaA, Abbott) and 9 years consulting. She has extensive industry experience in regulatory affairs, clinical research and clinical quality assurance, and a thorough knowledge of document management and electronic submissions.
Gavin Chait is a Data Scientist at Whythawk, which specializes in integrated open data consulting, and training for open knowledge, freedom of information, and economic development projects. He spent more than a decade in economic and development initiatives in South Africa. He was a commercial director at the Open Knowledge Foundation, and led the implementation of numerous open data projects around the world. Gavin has twenty years of experience in teaching at all academic levels, and is a passionate advocate for knowledge development through open access to data and freedom of information.
Kamila Novak, MSc, has been involved in clinical research since 1995, having worked in various positions in pharma and CROs. Since 2010, she has been working as an independent consultant in medical writing, auditing, training, project and risk management. She delivered dozens of courses in areas related to clinical research and project management. In August 2019, Kamila became a certified Lead Auditor for ISO 9001:2015. Kamila is a Core Team Member in the DIA GCP & QA, Clinical Research, and Project Management Communities.
Bartek has 18 years experience in clinical research business, mostly spent at largest global Contract Research Organizations. At Quintiles he was responsible for pioneer development of clinical start-up and regional contract departments. He served as executive member of clinical start-up leadership team at INC Research, acting as global head of site contract division. His most recent experience includes support for pharmaceutical organizations in various project specific roles. Bartek enables biopharma to get their sites up and running faster. He is author of several training programs about site contract related matters and successfully delivered to hundreds of individuals worldwide.
Shirley Price Professor and Academic Director, MSc, PhD, FBTS, FRBS, FRSC, ERT, MBritPharmacolSoc University of Surrey. Shirley is a graduate of the University of London completing her first degree in Biochemistry before coming to the University of Surrey to gain a MSc in Toxicology and then completing her PhD in Epigenetic Carcinogenesis. Shirley has over 25 years of experience in toxicology working across a number of fields. Having completed five years as an Associate Dean at the University of Surrey, Shirley is currently the Academic Director. Shirley’s academic career has provided her opportunities to educate and train many toxicologists and was instrumental in designing and delivering a training program in Applied Toxicology at Surrey. She remains actively involved in educating and training through a number of EU initiatives in the fields of Safety Sciences and Pharmaceutical Medicine and through her involvement with the British Toxicology Society. Shirley has been invited to be a member of a number of government committees and remains engaged with this work.
Siegfried Kasper O. Univ.-Prof. Dr.med.univ. Medical University of Vienna. Siegfried is a Professor of Psychiatry and Chair of the Department of Psychiatry and Psychotherapy at the Medical University of Vienna. He was educated in Innsbruck and Freiburg and gained clinical and research experience in psychiatry in Mannheim, Heidelberg, Maryland/USA and in Bonn. He is responsible for more than 640 scientific publications and 250 books or book chapters and is a member of editorial boards of numerous journals. He serves/served on the executive committees and advisory boards of several national and international societies and is the recipient of numerous national and international scientific and public awards and prizes.
Annette Mollet University of Basel. Annette is the Managing Director and Head of Education and Training at the European Center of Pharmaceutical Medicine (ECPM) of the University of Basel. She is a pharmacist by training and holds a PhD in Neurobiology from ETH in Zurich, Switzerland. After working several years at Roche both in Clinical Development and Medical Marketing, she joined Academia 20 years ago. ECPM was the managing entity of the IMI PharmaTrain program from 2009-2014. Annette is the president of the federal expert committee for radioactive drugs at Swissmedic.
Pierre Lafolie Associate Professior, Senior Lecturer, MD, PhD Karolinska Institutet. Pierre has practiced medicine in a wide range of medical areas (GP, psychiatry, geriatrics, pediatric, internal) and was Clinical Assessor at the Medical Products Agency. Since 2002, Pierre has been an Associated Professor and Course Director of Pharmaceutical Medicine at the Karolinska Institutet. He was also a member of several ethics committees.
Michel Goldman Full Professor, MD, PhD Institute for Interdisciplinary Innovation in Healthcare (I3h), Université libre de Bruxelles (ULB) Graduated as a medical doctor in 1978, Michel received his PhD in medical sciences in 1981. He is board certified in internal medicine and clinical biology. In 2009, Michel Goldman becomes the first Executive Director of the Innovative Medicines Initiative (IMI) where he was responsible for the launch of 59 public-private consortia. Michel is a professor of immunology and pharmacotherapy and leads the I3h at the ULB.
Peter G. Kremsner Chairperson and professor for Tropical Medicine, Travel Medicine and Parasitology and Director of the Institut für Tropenmedizin at the University Hospital in Tübingen. Peter is also President of the Centre de Recherches Médicales de Lambaréné, Gabun and Chief Executive Officer of the Comprehensive Infectious Disease Center of the University Hospital Tübingen. He is the author of more than 600 scientific publications and is a member of editorial boards of numerous journals. He has been a member of executive committees and advisory boards of several national and international organizations and he has received numerous national and international scientific and public awards and prizes.
Mag. Dietmar Eglhofer CEO, Co-Founder. Dietmar Eglhofer brings over 20 years of international leadership experience and experience in starting up companies. With ten years in Clinical Research and extensive hands-on experience in hiring and developing clinical professionals he developed models of source, train and hire for a leading CRO. He acts as the founder and Chief Executive Officer of the VIARES team.
Vladimir Mišik, PhD Partner, Co-founder. Vladimir (Vlado) Mišik brings over 30 years of biomedical research and development expertise into VIARES. He is a PhD scientist with years of oncology research at NIH in Bethesda, a pharmaceutical product development veteran serving in various senior roles in the industry, as well as the founder and partner of the clinical trial informatics platform LongTaal. Vlado is a regular speaker at international conferences and the author of more than 60 research articles and book chapters which include his on-going research on global trends of industry clinical trials. Vlado also serves as an editorial board member at Applied Clinical Research, Clinical Trials & Regulatory Affairs journal.
Pavel Farkas, PharmD, DPM Board Member. Pavel Farkas’ professional background and a degree in Clinical Pharmacy bring along over 25 years in clinical R&D in the pharmaceutical industry, most of which involve holding global positions in major generic companies. Currently he acts as a Senior Director of Biopharmaceutics and Clinical Development at Teva R&D. His competence and responsibilities have covered mostly pharmacokinetics, bioequivalence, as well as therapeutic equivalence and phase III studies for generic drug products, biosimilars and value-added generics, conducted for the EU, US, Canadian and CEE submissions. Equally relevant is his involvement and leadership in setting up concepts of clinical development programs compliant with respective regulatory requirements. Pavel has also been engaged as a lecturer for the post-graduate course in Pharmaceutical Medicine held at Charles University in Prague and regularly speaks at international pharmaceutical conferences. He acts as a member of the Bioequivalence and Clinical Development Working Group of Medicines for Europe and is the EU representative in the Steering Committee of AAPS Generic Pharmaceuticals Focus Group.
Roman Kollar, PhD Board Member Roman Kollar brings a blend of expertise starting with years of biomedical research at the NIH in Bethesda, further establishing the Pharmaceutical Biotechnology subject at the Slovak Technical University and also working for the diagnostic division of SanofiPasteur. Roman has been a speaker on several international conferences and he is the author of more than 20 research articles cited to date He lalter moved into business and functioned in different managerial positions, serving as a member of the executive boards in Heineken Slovensko the last 12 years, and later at Embraco Slovakia and is currently at FirstData Slovakia as the HR director. Roman has been elected chairman of the AgroFood Section of Slovak Chamber of Commerce in the past, as well as being an elected member of the executive committee of Association for Electric and Engineering Industry (ASEP) and is currently serving as the elected member on the executive board of the Slovak HR association (HRComm).
Mag. Martin Roy Board Member. Martin Roy has more than 20 years of leadership experience in top management positions. As CEO of Reed Exhibitions’ Austrian Business Unit and Chairman of the Reed Exhibitions’ Global Leadership Forum he has successfully led the change to a data driven business model. Martin’s focus is on disruptive technologies and he consults and invests in companies with the potential to transform their business.